Comparison of the efficacy of rabeprazole 10 mg and omeprazole 20 mg for the healing rapidity of peptic ulcer diseases

Sangwon Ji, Soo Kim Hyun, Woo Kim Jae, Kwan Jee Myeong, Wha Park Kwang, Young Uh, DongKi Lee, Suk Song Jae, Koo Baik Soon, Ok Kwon Sang

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Aim: Rabeprazole has been known to inhibit H+/K +-ATPase more rapidly than omeprazole, the prototype proton pump inhibitor (PPI). The aim of this study was to demonstrate equivalence between low-dose rabeprazole 10 mg and omeprazole 20 mg for the healing rapidity of active peptic ulcer and for improvement of symptoms. Also, the effect of CYP2C19 genotypes on ulcer healing rapidity was investigated. Methods: A total of 112 patients with active peptic ulcer were randomized to receive either rabeprazole 10 mg q.d. or omeprazole 20 mg q.d. for 6 weeks. The remaining ratios (%) and complete healing of the ulcer were determined by endoscopy at 1 week and 6 weeks of treatment. The severity of ulcer pain was also investigated during treatment. CYP2C19 genotype was determined by the polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method. Results: The remaining ratio of peptic ulcers after 1 week and the complete healing rate after 6 weeks in the rabeprazole versus omeprazole group were 45.5% versus 50.3% (P = 0.475) and 80.6% versus 87.0% (P = 0.423), respectively. CYP2C19 genotypes had no effect on the remaining ratio of peptic ulcers after 1 week and the healing rate of peptic ulcers after 6 weeks in both groups. The proportions of patients with symptom improvement or resolution were comparable between the two groups. Conclusion: Low-dose rabeprazole 10 mg has a similar efficacy for the healing rapidity of active peptic ulcer disease and symptom improvement compared with standard-dose omeprazole 20 mg.

Original languageEnglish
Pages (from-to)1381-1387
Number of pages7
JournalJournal of Gastroenterology and Hepatology (Australia)
Volume21
Issue number9
DOIs
Publication statusPublished - 2006 Jan 1

Fingerprint

Rabeprazole
Omeprazole
Peptic Ulcer
Ulcer
Genotype
Proton-Translocating ATPases
Proton Pump Inhibitors
Restriction Fragment Length Polymorphisms
Endoscopy
Pain
Polymerase Chain Reaction
Therapeutics

All Science Journal Classification (ASJC) codes

  • Gastroenterology
  • Hepatology

Cite this

Ji, Sangwon ; Hyun, Soo Kim ; Jae, Woo Kim ; Myeong, Kwan Jee ; Kwang, Wha Park ; Uh, Young ; Lee, DongKi ; Jae, Suk Song ; Soon, Koo Baik ; Sang, Ok Kwon. / Comparison of the efficacy of rabeprazole 10 mg and omeprazole 20 mg for the healing rapidity of peptic ulcer diseases. In: Journal of Gastroenterology and Hepatology (Australia). 2006 ; Vol. 21, No. 9. pp. 1381-1387.
@article{2c3638839a8847359b4ef06216f8e222,
title = "Comparison of the efficacy of rabeprazole 10 mg and omeprazole 20 mg for the healing rapidity of peptic ulcer diseases",
abstract = "Aim: Rabeprazole has been known to inhibit H+/K +-ATPase more rapidly than omeprazole, the prototype proton pump inhibitor (PPI). The aim of this study was to demonstrate equivalence between low-dose rabeprazole 10 mg and omeprazole 20 mg for the healing rapidity of active peptic ulcer and for improvement of symptoms. Also, the effect of CYP2C19 genotypes on ulcer healing rapidity was investigated. Methods: A total of 112 patients with active peptic ulcer were randomized to receive either rabeprazole 10 mg q.d. or omeprazole 20 mg q.d. for 6 weeks. The remaining ratios ({\%}) and complete healing of the ulcer were determined by endoscopy at 1 week and 6 weeks of treatment. The severity of ulcer pain was also investigated during treatment. CYP2C19 genotype was determined by the polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method. Results: The remaining ratio of peptic ulcers after 1 week and the complete healing rate after 6 weeks in the rabeprazole versus omeprazole group were 45.5{\%} versus 50.3{\%} (P = 0.475) and 80.6{\%} versus 87.0{\%} (P = 0.423), respectively. CYP2C19 genotypes had no effect on the remaining ratio of peptic ulcers after 1 week and the healing rate of peptic ulcers after 6 weeks in both groups. The proportions of patients with symptom improvement or resolution were comparable between the two groups. Conclusion: Low-dose rabeprazole 10 mg has a similar efficacy for the healing rapidity of active peptic ulcer disease and symptom improvement compared with standard-dose omeprazole 20 mg.",
author = "Sangwon Ji and Hyun, {Soo Kim} and Jae, {Woo Kim} and Myeong, {Kwan Jee} and Kwang, {Wha Park} and Young Uh and DongKi Lee and Jae, {Suk Song} and Soon, {Koo Baik} and Sang, {Ok Kwon}",
year = "2006",
month = "1",
day = "1",
doi = "10.1111/j.1440-1746.2006.04314.x",
language = "English",
volume = "21",
pages = "1381--1387",
journal = "Journal of Gastroenterology and Hepatology (Australia)",
issn = "0815-9319",
publisher = "Wiley-Blackwell",
number = "9",

}

Comparison of the efficacy of rabeprazole 10 mg and omeprazole 20 mg for the healing rapidity of peptic ulcer diseases. / Ji, Sangwon; Hyun, Soo Kim; Jae, Woo Kim; Myeong, Kwan Jee; Kwang, Wha Park; Uh, Young; Lee, DongKi; Jae, Suk Song; Soon, Koo Baik; Sang, Ok Kwon.

In: Journal of Gastroenterology and Hepatology (Australia), Vol. 21, No. 9, 01.01.2006, p. 1381-1387.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Comparison of the efficacy of rabeprazole 10 mg and omeprazole 20 mg for the healing rapidity of peptic ulcer diseases

AU - Ji, Sangwon

AU - Hyun, Soo Kim

AU - Jae, Woo Kim

AU - Myeong, Kwan Jee

AU - Kwang, Wha Park

AU - Uh, Young

AU - Lee, DongKi

AU - Jae, Suk Song

AU - Soon, Koo Baik

AU - Sang, Ok Kwon

PY - 2006/1/1

Y1 - 2006/1/1

N2 - Aim: Rabeprazole has been known to inhibit H+/K +-ATPase more rapidly than omeprazole, the prototype proton pump inhibitor (PPI). The aim of this study was to demonstrate equivalence between low-dose rabeprazole 10 mg and omeprazole 20 mg for the healing rapidity of active peptic ulcer and for improvement of symptoms. Also, the effect of CYP2C19 genotypes on ulcer healing rapidity was investigated. Methods: A total of 112 patients with active peptic ulcer were randomized to receive either rabeprazole 10 mg q.d. or omeprazole 20 mg q.d. for 6 weeks. The remaining ratios (%) and complete healing of the ulcer were determined by endoscopy at 1 week and 6 weeks of treatment. The severity of ulcer pain was also investigated during treatment. CYP2C19 genotype was determined by the polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method. Results: The remaining ratio of peptic ulcers after 1 week and the complete healing rate after 6 weeks in the rabeprazole versus omeprazole group were 45.5% versus 50.3% (P = 0.475) and 80.6% versus 87.0% (P = 0.423), respectively. CYP2C19 genotypes had no effect on the remaining ratio of peptic ulcers after 1 week and the healing rate of peptic ulcers after 6 weeks in both groups. The proportions of patients with symptom improvement or resolution were comparable between the two groups. Conclusion: Low-dose rabeprazole 10 mg has a similar efficacy for the healing rapidity of active peptic ulcer disease and symptom improvement compared with standard-dose omeprazole 20 mg.

AB - Aim: Rabeprazole has been known to inhibit H+/K +-ATPase more rapidly than omeprazole, the prototype proton pump inhibitor (PPI). The aim of this study was to demonstrate equivalence between low-dose rabeprazole 10 mg and omeprazole 20 mg for the healing rapidity of active peptic ulcer and for improvement of symptoms. Also, the effect of CYP2C19 genotypes on ulcer healing rapidity was investigated. Methods: A total of 112 patients with active peptic ulcer were randomized to receive either rabeprazole 10 mg q.d. or omeprazole 20 mg q.d. for 6 weeks. The remaining ratios (%) and complete healing of the ulcer were determined by endoscopy at 1 week and 6 weeks of treatment. The severity of ulcer pain was also investigated during treatment. CYP2C19 genotype was determined by the polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method. Results: The remaining ratio of peptic ulcers after 1 week and the complete healing rate after 6 weeks in the rabeprazole versus omeprazole group were 45.5% versus 50.3% (P = 0.475) and 80.6% versus 87.0% (P = 0.423), respectively. CYP2C19 genotypes had no effect on the remaining ratio of peptic ulcers after 1 week and the healing rate of peptic ulcers after 6 weeks in both groups. The proportions of patients with symptom improvement or resolution were comparable between the two groups. Conclusion: Low-dose rabeprazole 10 mg has a similar efficacy for the healing rapidity of active peptic ulcer disease and symptom improvement compared with standard-dose omeprazole 20 mg.

UR - http://www.scopus.com/inward/record.url?scp=33746595230&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33746595230&partnerID=8YFLogxK

U2 - 10.1111/j.1440-1746.2006.04314.x

DO - 10.1111/j.1440-1746.2006.04314.x

M3 - Article

VL - 21

SP - 1381

EP - 1387

JO - Journal of Gastroenterology and Hepatology (Australia)

JF - Journal of Gastroenterology and Hepatology (Australia)

SN - 0815-9319

IS - 9

ER -